Archive \ Volume.13 2022 Issue 3

Polypharmacy and Medication Compliance among Patients with Type 2 Diabetes in Oman: A Cross-Sectional Study

Asma Al Shidhani, Asma Al Salmani, Yaqoub Al Saidi, Marwa Al Shehhi, Hoor Al Khanjari, Mahla Al Aamri, Fatma Al Hadabi

The goal of this study was to estimate the prevalence of polypharmacy and medication compliance among patients with T2DM at a primary care clinic in Muscat, Oman, to determine whether various sociodemographic and clinical factors were associated with polypharmacy and to assess relationships between polypharmacy, compliance, and self-related health. It is a cross-sectional study conducted between September and November 2019 and included all adult T2DM patients attending the clinic. Data were collected using a questionnaire, face-to-face interviews, and electronic medical records. A total of 202 T2DM patients were included. The majority were female (56.9%) and ≥60 years old (45.5%). Most had two or more chronic health conditions (66.3%). The prevalence of polypharmacy was 83.1%. Overall, 65% and 92% of patients reported a high level of adherence to treatment and good-to-excellent health, respectively. In conclusion, Polypharmacy was common among T2DM patients and was significantly associated with age, common comorbidities, and T2DM duration.

Downloads: 38
Views: 61

How to cite:
Al Shidhani A, Al Salmani A, Al Saidi Y, Al Shehhi M, Al Khanjari H, Al Aamri M, et al. Polypharmacy and Medication Compliance among Patients with Type 2 Diabetes in Oman: A Cross-Sectional Study. Arch Pharm Pract. 2022;13(3):48-53.
Al Shidhani, A., Al Salmani, A., Al Saidi, Y., Al Shehhi, M., Al Khanjari, H., Al Aamri, M., & Al Hadabi, F. (2022). Polypharmacy and Medication Compliance among Patients with Type 2 Diabetes in Oman: A Cross-Sectional Study. Archives of Pharmacy Practice, 13(3), 48-53.

Download Citation

1.        Noale M, Veronese N, Perin PC, Pilotto A, Tiengo A, Crepaldi G, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016;53(2):323-30. doi:10.1007/s00592-015-0790-4

2.        Lee EA, Brettler JW, Kanter MH, Steinberg SG, Khang P, Distasio CC, et al. Refining the Definition of Polypharmacy and Its Link to Disability in Older Adults: Conceptualizing Necessary Polypharmacy, Unnecessary Polypharmacy, and Polypharmacy of Unclear Benefit. Perm J. 2020;24:18.212. doi:10.7812/TPP/18.212

3.        Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectr. 2002;15(4):240-8. doi:10.2337/diaspect.15.4.240

4.        Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007; 24(1):14-9. doi:10.1093/fampra/cml067

5.        Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: A cross-sectional analysis of data from The English Longitudinal Study of Ageing (ELSA). BMJ Open. 2018;8(3):e0202701. doi:10.1136/bmjopen-2017-020270

6.        Lim LM, McStea M, Chung WW, Azmi NN, Abdul Aziz SS, Alwi S, et al. Prevalence, risk factors, and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia. PLoS One. 2017;12(3):e0173466. doi:10.1371/journal.pone.0173466

7.        Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One. 2014;9(6):e98043. doi:10.1371/journal.pone.0098043

8.        Alsuwaidan A, Almedlej N, Alsabti S, Daftardar O, Al Deaji F, Al Amri A, et al. A comprehensive overview of polypharmacy in elderly patients in Saudi Arabia. Geriatrics. 2019;4(2):36.  doi:10.3390/geriatrics4020036

9.        Bradley D, Hsueh W. Type 2 diabetes in the elderly: Challenges in a unique patient population. J Geriatr Med Gerontol 2016;2(2):14. doi:10.23937/2469-5858/1510014

10.      Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843

11.      Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51-62. doi:10.1016/j.cmet.2016.06.021

12.      Dobrică EC, Găman MA, Cozma MA, Bratu OG, Stoian AP, Diaconu CC. Polypharmacy in type 2 diabetes mellitus: Insights from an internal medicine department. Medicina (Kaunas). 2019;55(8):436. doi:10.3390/medicina55080436

13.      Alwhaibi M, Balkhi B, Alhawassi TM, Alkofide H, Alduhaim N, Alabdulali R, et al. Polypharmacy among patients with diabetes: A cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018;8:e020852. doi:10.1136/bmjopen-2017-020852

14.      Feng X, Tan X, Riley B, Zheng T, Bias TK, Becker JB. Prevalence and geographic 14 variations of polypharmacy among West Virginia Medicaid beneficiaries. Ann Pharmacother. 2017;51(11):981-9. doi:10.1177/1060028017717017

15.      Horii T, Iwasawa M, Kabeya Y, Atuda K. Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterized by drug class and patient characteristics: A Japanese database analysis. Sci Rep. 2019;9(1):12992. doi:10.1038/s41598-019-49424-2

16.      Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74. doi:10.1097/00005650-198601000-00007

17.      Vyas A, Kang F, Barbour M. Association between polypharmacy and health-related quality of life among US adults with cardiometabolic risk factors. Qual Life Res. 2020; 29(4):977-86. doi:10.1007/s11136-019-02377-5

18.      Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187-95. doi:10.1111/j.1365-2125.2006.02744.x

19.      Gadsby R, Galloway M, Barker P, Sinclair A. Prescribed medicines for elderly frail people with diabetes resident in nursing homes: Issues of polypharmacy and medication costs. Diabet Med. 2012;29(1):136-9. doi:10.1111/j.1464-5491.2011.03494.x

20.      Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408-12. doi:10.2337/diacare.26.5.1408

21.      Abu Farha RK, Mukattash TL, Al-Sakran L, Abu Hammour K, Zawiah M. Prevalence and predictors of polypharmacy in Jordanian hospitalised patients: A cross-sectional Study. Int J Clin Pract. 2021;75(4):e13742. doi:10.1111/ijcp.13742

22.      Balkhi B, AlQahtani N, Alwhaibi M, Alshammari TM, Alhawassi TM, Mahmoud MA, et al. Prevalence and Factors Associated With Polypharmacy Use Among Adult Patients in Saudi Arabia. J Patient Saf. 2021;17(8):e1119-24. doi:10.1097/PTS.0000000000000439

23.      Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243-52. doi:10.1185/03007995.2016.1168291

24.      Li J, Chattopadhyay K, Xu M, Chen Y, Hu F, Wang X, et al. Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients at a tertiary care department in Ningbo, China: a retrospective database study. PLoS One. 2019;14(7):e0220047. doi:10.1371/journal.pone

25.      Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: Mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich). 2011;13(4):244-51. doi:10.1111/j.1751-7176.2011.00434.x

26.      Rieckert A, Trampisch US, Klaaßen-Mielke R, Drewelow E, Esmail A, Johansson T, et al. Polypharmacy in older patients with chronic diseases: A cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19(1):113. doi:10.1186/s12875-018-0795-5

27.      Bierman AS, Pugh MJ, Dhalla I, Amuan M, Fincke BG, Rosen A, et al. Sex differences in inappropriate prescribing among elderly veterans. Am J Geriatr Pharmacother. 2007;5(2):147-61. doi:10.1016/j.amjopharm.2007.06.005

28.      Zelko E, Klemenc-Ketis Z, Tusek-Bunc K. Medication adherence in elderly with polypharmacy living at home: A systematic review of existing studies. Mater Sociomed. 2016;28(2):129-32. doi:10.5455/msm.2016.28.129-132

29.      Cárdenas-Valladolid J, Martín-Madrazo C, Salinero-Fort MA, de-Santa Pau EC, Abánades-Herranz JC, de Burgos-Lunar C. Prevalence of adherence to treatment in homebound elderly people in primary health care: A descriptive, cross-sectional, multicentre study. Drugs Aging. 2010;27(8):641-51. doi:10.2165/11537320-000000000-00000

30.      Badawi G, Gariépy G, Pagé V, Schmitz N. Indicators of self-rated health in the Canadian population with diabetes. Diabet Med 2012;29(8):1021-8. doi:10.1111/j.1464-5491.2012.03571.x

31.      Bazargan M, Smith J, Saqib M, Helmi H, Assar S. Associations between polypharmacy, self-rated health, and depression in African American older adults: Mediators and moderators. Int J Environ Res Public Health. 2019;16(9):1574. doi:10.3390/ijerph16091574

32.      World Health Organization. Regulatory situation of herbal medicines: A worldwide review. Available from: Accessed: Jun 2020


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.